ArticleThe oncologist2018

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Gerald Edelman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.